X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ceritinib (343) 343
crizotinib (223) 223
oncology (193) 193
index medicus (181) 181
chemotherapy (149) 149
humans (140) 140
alectinib (123) 123
open-label (107) 107
anaplastic lymphoma kinase (105) 105
alk (86) 86
cell lung-cancer (86) 86
carcinoma, non-small-cell lung - drug therapy (85) 85
lung neoplasms - drug therapy (84) 84
resistance (77) 77
mutation (75) 75
lung cancer (71) 71
lymphomas (68) 68
nsclc (68) 68
respiratory system (62) 62
lung cancer, non-small cell (58) 58
non-small cell lung cancer (58) 58
protein kinase inhibitors - therapeutic use (57) 57
receptor protein-tyrosine kinases - genetics (54) 54
lung neoplasms - genetics (53) 53
antineoplastic agents - therapeutic use (52) 52
male (51) 51
receptor protein-tyrosine kinases - antagonists & inhibitors (51) 51
carcinoma, non-small-cell lung - genetics (50) 50
brain metastases (47) 47
cancer (47) 47
middle aged (45) 45
female (44) 44
pyrimidines - therapeutic use (44) 44
hemic and lymphatic diseases (42) 42
crizotinib resistance (40) 40
lung neoplasms - pathology (40) 40
pharmacology & pharmacy (40) 40
safety (39) 39
metastasis (38) 38
protein kinase inhibitors - pharmacology (38) 38
sulfones - therapeutic use (37) 37
acquired-resistance (36) 36
animals (36) 36
brigatinib (36) 36
carcinoma, non-small-cell lung - pathology (35) 35
kinases (35) 35
adult (34) 34
single-arm (34) 34
cancer therapies (33) 33
treatment outcome (31) 31
eml4-alk fusion gene (30) 30
pyrazoles - therapeutic use (30) 30
pyridines - therapeutic use (30) 30
antineoplastic agents - pharmacology (29) 29
care and treatment (29) 29
mutations (29) 29
inhibitors (28) 28
alk inhibitors (27) 27
eml4-alk (26) 26
identification (26) 26
inhibitor (26) 26
lymphoma (26) 26
aged (25) 25
non-small-cell lung cancer (25) 25
survival (25) 25
tumors (25) 25
receptor protein-tyrosine kinases - metabolism (24) 24
hematology, oncology and palliative medicine (23) 23
patients (23) 23
protein-tyrosine kinase (23) 23
pyrimidines - pharmacology (23) 23
cell line, tumor (22) 22
drug therapy (22) 22
drug resistance, neoplasm (21) 21
metastases (21) 21
egfr (20) 20
genetic aspects (20) 20
sulfones - pharmacology (20) 20
alk inhibitor (19) 19
drug resistance, neoplasm - genetics (19) 19
review (19) 19
tyrosine (19) 19
antitumor-activity (18) 18
drug resistance (18) 18
gefitinib (18) 18
gene (18) 18
lorlatinib (18) 18
proteins (18) 18
research (18) 18
analysis (17) 17
drug resistance, neoplasm - drug effects (17) 17
gene rearrangement (17) 17
multicenter phase-ii (17) 17
pulmonary/respiratory (17) 17
tyrosine kinase inhibitors (17) 17
antineoplastic agents - adverse effects (16) 16
article (16) 16
carcinoma, non-small-cell lung - metabolism (16) 16
chemistry, medicinal (16) 16
clinical trials (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Internal Medicine, ISSN 0918-2918, 2019
We herein report a 75-year-old woman with insulin-treated diabetes and metastatic anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer who... 
hyperglycemia | insulin resistance | ceritinib
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2018, Volume 36, Issue 22, pp. 2251 - 2258
Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK)... 
TRIALS | ONCOLOGY | CERITINIB | ADENOCARCINOMA | ALECTINIB | INHIBITORS | PHASE-3 | RETROSPECTIVE ANALYSIS
Journal Article
by Qi, XL and Ma, W and Li, S and Zhou, CC
LUNG CANCER, ISSN 0169-5002, 08/2014, Volume 85, Issue 2, pp. 335 - 336
Journal Article
NATURE CHEMICAL BIOLOGY, ISSN 1552-4450, 12/2017, Volume 13, Issue 12, pp. 1204 - 1204
The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule... 
CERITINIB | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMOTHERAPY
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2014, Volume 20, Issue 22, pp. 5686 - 5696
Purpose: The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a standard therapy for patients with ALK-rearranged non-small cell lung cancer... 
CELL LUNG-CANCER | ANAPLASTIC LYMPHOMA KINASE | NVP-TAE684 | ONCOLOGY | CERITINIB | EML4-ALK FUSION GENE | SENSITIVITY | CH5424802 | CRIZOTINIB RESISTANCE | NEUROBLASTOMA | IDENTIFICATION | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Lung Neoplasms - metabolism | Tomography, X-Ray Computed | Dose-Response Relationship, Drug | Piperidines - pharmacology | DNA Mutational Analysis | Inhibitory Concentration 50 | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrazoles - pharmacology | Pyridines - therapeutic use | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Models, Molecular | Lactams, Macrocyclic - pharmacology | Benzoquinones - pharmacology | Drug Resistance, Neoplasm - genetics | Receptor Protein-Tyrosine Kinases - genetics | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Lung Neoplasms - diagnostic imaging | Protein Conformation | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Carbazoles - pharmacology | Receptor Protein-Tyrosine Kinases - chemistry | Index Medicus | gatekeeper mutation | crizotinib | ALK-rearranged NSCLC | alectinib (RO5424802 | resistance | ceritinib (LDK378)
Journal Article
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, ISSN 0732-183X, 06/2019, Volume 37, Issue 16, pp. 1370 - 1379
PURPOSE Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical... 
ONCOLOGY | CERITINIB | ALECTINIB | CRIZOTINIB | OPEN-LABEL | INHIBITOR | ROS1 | PF-06463922
Journal Article
Neurology, ISSN 0028-3878, 07/2019, Volume 93, Issue 5, pp. 217 - 219
Journal Article
International Journal of Research in Pharmaceutical Sciences, 2018, Volume 9, Issue 4, pp. 1141 - 1145
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2018, Volume 36, Issue 12, pp. 1199 - 1206
PurposeAdvanced anaplastic lymphoma kinase (ALK) fusion-positive non-small-cell lung cancers (NSCLCs) are effectively treated with ALK tyrosine kinase... 
GENE | ONCOLOGY | CERITINIB | CRIZOTINIB | OPEN-LABEL | SINGLE-ARM | INHIBITOR | IDENTIFICATION | FUSION VARIANT | NSCLC PATIENTS | CHEMOTHERAPY | ORIGINAL REPORTS
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue 10, pp. 2028 - 2030
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2018, Volume 36, Issue 26, pp. 2693 - 2701
PurposeIn patients with crizotinib-treated, anaplastic lymphoma kinase gene (ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC), initial disease... 
ALK | MULTICENTER | SOLID TUMORS | ONCOLOGY | CERITINIB | PHASE-1 TRIAL | CRIZOTINIB | OPEN-LABEL | WHOLE-BODY | SINGLE-ARM | CHEMOTHERAPY | Index Medicus
Journal Article
CLINICAL NUCLEAR MEDICINE, ISSN 0363-9762, 11/2016, Volume 41, Issue 11, pp. 879 - 879
Anaplastic lymphoma kinase (AM) positive non small cell lung cancers (NSCLC) account for 3% to 7% of all NSCLC and require a standard treatment by crizotinib.... 
INHIBITOR CERITINIB | NSCLC | PET/CT | F-18-FDG | RECEPTOR | CRIZOTINIB RESISTANCE | ceritinib | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
Chinese Journal of New Drugs, ISSN 1003-3734, 11/2017, Volume 26, Issue 22, pp. 2719 - 2725
Journal Article
Cancer Discovery, ISSN 2159-8274, 10/2016, Volume 6, Issue 10, pp. 1118 - 1133
Journal Article
Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 31, pp. 22137 - 22146
Anaplastic lymphoma kinase ( ) inhibitors are the mainstay treatment for patients with non-small cell lung carcinoma (NSCLC) harboring a rearrangement of the... 
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 02/2019, Volume 163, pp. 169 - 182
The emergence of various drug-resistant ( ) strains has necessitated the exploration of new drugs that lack cross-resistance with existing therapeutics. By... 
Pyrimidine derivatives | Dihydrofolate reductase inhibitors | Antimycobacterial | Ceritinib | CHEMISTRY, MEDICINAL | TRIMETHOPRIM | BIOLOGICAL EVALUATION | Index Medicus
Journal Article
Revue des Maladies Respiratoires Actualites, ISSN 1877-1203, 05/2015, Volume 7, Issue 2, pp. 138 - 145
Screening, targeted therapies, mutations, maintenance. . . Thoracic oncology is progressing quickly. This trend was confirmed in 2014, with important... 
Crizotinib | Ramucirumab | Ceritinib | Nintedani
Journal Article
JOURNAL OF THORACIC ONCOLOGY, ISSN 1556-0864, 07/2019, Volume 14, Issue 7, pp. 1255 - 1265
Introduction: In an earlier report of the ASCEND-8 study (open-label, phase I, three-arm study, treatment-naive patients and pre-treated patients with... 
ALK receptor tyrosine kinase | Food effect | NSCLC | ONCOLOGY | RESPIRATORY SYSTEM | MEAL | CRIZOTINIB | OPEN-LABEL | Ceritinib | CHEMOTHERAPY
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.